The largest database of trusted experimental protocols

Anti il10r

Manufactured by BioXCell

Anti-IL10R is a laboratory reagent that targets the interleukin-10 receptor (IL-10R). It is used in research applications to study the role of IL-10 signaling in various biological processes.

Automatically generated - may contain errors

4 protocols using anti il10r

1

Murine Model of Visceral Leishmaniasis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Female C57BL/6 CD45.1, CD45.2, and RAG2-/- mice were obtained from Charles River (UK). MiR-132/212-/- mice (complete knockouts) were provided by Dr Richard Goodman (Vollum Institute, Oregon Health & Science University, USA). IL-10-/- mice were provided by Dr Anne O’Garra (Francis Crick Institute, UK) and were crossed with WT CD45.2 C57BL/6 mice to generate IL-10+/- heterozygotes. All mice were bred in house, maintained under specific pathogen-free conditions and used at 6 – 12 weeks of age. The Ethiopian strain of L. donovani (LV9) was maintained by passage in RAG-2-/- mice. Mice were infected i.v. with 100x106 amastigotes via the tail vein. Parasite doses of 10 and 30x106 were also used where indicated. Parasite burden was expressed as Leishman-Donovan units (LDU; the number of parasites per 1,000 host cell nuclei × organ weight in mg)[48 (link)]. To allow comparison between these experiments, we normalised LDU to the levels observed in WT mice (relative LDU). For IL-10R neutralisation experiments mice were infected with L. donovani and received anti-IL10R (Clone: 1B1.3A from Bio X Cell) or IgG isotype control (SIGMA) injections at day 0, 14, and 21 p.i. at 0.5mg mAb/injection.
+ Open protocol
+ Expand
2

Immunotherapy in Murine Tumor Models

Check if the same lab product or an alternative is used in the 5 most similar protocols
Mice were injected with B16-OVA cells (105, intradermally), TC-1-P3(A15) (105, subcutaneously) or E.G7-OVA (5 × 105, subcutaneously) and when the tumor diameter reached 4–5 mm, they received intratumoral administration of OVA protein (0.5 mg/mouse) or EDA-HPVE7 immunogen [23 (link)] (2 nanomoles) combined with Imiquimod cream (Meda-Aldara™; topical application; 2.5 mg/mouse), poly(I:C) (Amersham; 50 μg/mouse; intratumor) or left untreated. Tumor-free mice received similar immunizations by subcutaneous route. At different time-points they were sacrificed and splenocytes, lymph node cells or tumor-infiltrating cells were obtained for characterization. Additionally, they received i.p. injection of anti-IL-10R (500 μg), anti-PD-L1 (200 μg) or the corresponding isotype control antibodies (all from BioXcell).
+ Open protocol
+ Expand
3

Helicobacter hepaticus Infection in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
Helicobater hepaticus (1 X 108 CFU strain 51449; ATCC) was gavaged to mice on 0, 2, 4 d. Mice also received 1mg of anti-IL-10R (BioXCell; 1B1.2) antibody via i.p. injection on 0, 7, 14, 21 d after H. hepaticus infection (15 (link)).
+ Open protocol
+ Expand
4

Murine BMDM Isolation and Stimulation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Murine BMDMs were obtained as previously described (Xu et al., 2012 (link)) and maintained in DMEM (HyClone) supplemented with 10% FBS (Gibco) and 10% supernatant of L929 cell as conditioned medium providing macrophage colony-stimulating factor (M-CSF, identified as complete medium). Briefly, bone marrow cells were extracted and cultured with complete medium for 5 days to derive BMDMs. Cell culture grade LPS and Pam3CSK4 were purchased from Invivogen and were used at a concentration of 10 ng/ml unless otherwise specified. SF1670 were from Selleck. anti-IL10R, anti-IgG, and anti-TNF were purchased from BioXCell. anti-IL10R or anti-IgG was added 30 min prior to LPS stimulation and were present throughout LPS exposure.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!